---
schema_version: "secwatch.filing_event.v1"
accession: "0001962918-24-000117"
form_type: "8-K/A"
ticker: null
cik: "0001962918"
company_name: "ACELYRIN, Inc."
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T06:25:35.979298+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ACELYRIN estimates ~$11.5M restructuring charges; cuts 40 jobs, halts izokibep in HS/PsA/AxSpa

## Summary
- Workforce reduced by 40 employees (~1/3 headcount); one-time severance costs estimated at $4.3M.
- Suspension of izokibep development in HS, PsA, AxSpa; focus shifts to lonigutamab for thyroid eye disease.
- Cancellation of manufacturing services yields net charge of ~$7.2M ($42.9M cash expense netted with $35.7M credit voucher).
- Q3 2024 restructuring charges preliminarily estimated at $3.6M severance plus full $7.2M manufacturing cancellation charge.
- Credit voucher expected to offset future manufacturing costs for lonigutamab through Q1 2026.

## SEC filing metadata
- accession: 0001962918-24-000117
- form_type: 8-K/A
- cik: 0001962918
- company_name: ACELYRIN, Inc.
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1962918/000196291824000117/0001962918-24-000117-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1962918/000196291824000117/slrn-20240810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001962918-24-000117
- JSON: https://secwatch.observer/filing/0001962918-24-000117.json
- Plain text: https://secwatch.observer/filing/0001962918-24-000117.txt

## Key facts
- Restructurings & Charges
  ACELYRIN, Inc. announced a restructuring with charges of approximately $7.2 million affecting the Company; cancellation of services under a manufacturing agreement related to suspension of new internal development of izokibep in HS, PsA and AxSpa.
  - Type: restructuring
  - Charge: approximately $7.2 million
  - Affected area: the Company; cancellation of services under a manufacturing agreement related to suspension of new internal development of izokibep in HS, PsA and AxSpa
  source text: the Company now estimates that it will incur net restructuring charges of approximately $7.2 million consisting of $42.9 million of cash expense in connection with such cancellation of services netted against a $35.7 million credit voucher
  evidence_url: https://www.sec.gov/Archives/edgar/data/1962918/000196291824000117/0001962918-24-000117-index.htm
- Restructurings & Charges
  ACELYRIN, Inc. announced a restructuring with charges of approximately $4.3 million affecting the Company; workforce reduction connected with plan to suspend new internal investment in development of izokibep in HS, PsA and AxSpa (40 people, or approximately 1/3 of the Company’s then-existing headcount).
  - Type: restructuring
  - Charge: approximately $4.3 million
  - Affected area: the Company; workforce reduction connected with plan to suspend new internal investment in development of izokibep in HS, PsA and AxSpa
  - Headcount: 40 people, or approximately 1/3 of the Company’s then-existing headcount
  source text: the Company now estimates that it will incur restructuring charges totaling approximately $4.3 million consisting of cash-based expenses related to one-time employee severance payments and benefits
  evidence_url: https://www.sec.gov/Archives/edgar/data/1962918/000196291824000117/0001962918-24-000117-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.